Athersys Inc. (NASDAQ: ATHX) is a clinical-stage biotechnology company that is an established international leader in the field of regenerative medicine. The company has developed a patented and potential breakthrough "off the shelf" stem cell product, MultiStem® that is being evaluated in multiple clinical trials. Active clinical development programs include treating Inflammatory Bowel Disease (partnered with Pfizer), ischemic stroke, heart disease, and to prevent graft versus host disease and other complications in patients being treated for leukemia or related conditions. The company also has active collaborations with leading scientists and internationally renowned clinical and research institutions, and has broad intellectual property on the MultiStem platform, with over 50 issued patents.
Athersys’ MultiStem® is a best-in-class product with the following features:
- MultiStem has been shown to enhance healing and tissue repair in multiple ways and exhibits a drug-like profile (i.e. cleared from the body over time).
- Unlike alternative cell therapy platforms, MultiStem can be produced on an industrial scale, in a well-validated and reproducible manner.
- MultiStem exhibits a consistent safety profile.
- Multiple clinical indications and commercial opportunities can be pursued in parallel, using a highly efficient development approach with multiple partners and collaborators.